{"title":"Useful Predictor for Exacerbation of Esophagogastric Varices after Hepatitis C Virus Eradication by Direct-Acting Antivirals","link":"https://www.preprints.org/manuscript/202406.0243/v1","date":1717577623000,"content":"To clarify the risk factors for aggravation of esophagogastric varices (EGV) after hepatitis C virus (HCV) eradication with direct-acting antiviral (DAA) therapy, we enrolled 167 consecutive patients with HCV-related compensated cirrhosis who achieved a sustained virological response (SVR) after DAA therapy. During a median of 69 months, EGV was aggravated in 42 (25%) patients despite SVR. The cumulative 1, 3, 5, and 10-year aggravated EGV rates were 7%, 23%, 25%, and 27%, respectively. Multivariate analysis identified platelet count","author":"","siteTitle":"Preprints.org - The Multidisciplinary Preprint Platform","siteHash":"abac34b0506002eba4392ac15186820b9b5d7a0f2e5fce3a3511408258fb1a7e","entryHash":"2b03729cc376e5e9f733f66936f39c7a49380e03064d15ab3c909c7eeded899f","category":"Interdisciplinary"}